Current approach to seronegative myasthenia

Area of Science:

• Neurology
• Immunology
• Clinical Medicine

Background:

• Patients with neuromuscular transmission defects but negative for acetylcholine receptor (AChR) or muscle-specific kinase (MuSK) antibodies present a diagnostic challenge.
• These seronegative myasthenia gravis (MG) cases may involve low-affinity antibodies or late-onset congenital myasthenic syndromes.
• Understanding these distinct patient groups is crucial for effective management.

Purpose of the Study:

• To outline a practical approach for evaluating and managing patients with seronegative myasthenia.
• To differentiate seronegative MG from other neuromuscular junction disorders.
• To discuss potential therapeutic considerations for this specific patient cohort.

Main Methods:

• Review of existing literature on seronegative myasthenia.
• Analysis of diagnostic criteria for neuromuscular transmission defects.
• Discussion of differential diagnoses including congenital myasthenic syndromes.
• Exploration of antibody testing nuances (e.g., low-affinity antibodies).

Main Results:

• Seronegative status does not exclude autoimmune neuromuscular junction disease.
• Congenital myasthenic syndromes represent a significant differential diagnosis.
• Low-affinity antibodies may be present but require specialized assays.
• A systematic diagnostic workup is essential.

Conclusions:

• A structured approach is necessary for patients with electrophysiological evidence of neuromuscular transmission defects and absent common autoantibodies.
• Consideration of congenital myasthenic syndromes and low-affinity antibodies is vital.
• Tailored therapeutic strategies are required for seronegative myasthenia patients.